Ultomiris market outlook points to faster growth as rare-disease demand rises
The Ultomiris market is expanding as more patients are diagnosed with rare autoimmune diseases and as healthcare systems invest more in biologic therapies. The Business Research Company says North America led the market in 2025, while long-acting complement inhibitors and subcutaneous delivery could shape future demand.
Why it matters: - The Ultomiris market is tied to rare autoimmune diseases that require ongoing specialty treatment and monitoring. - Growing demand for therapies that reduce treatment burden could support wider use of Ultomiris and similar biologic drugs. - The market outlook matters to drug developers, hospitals and payers because treatment access depends on diagnosis, reimbursement and care delivery models.
What happened: - The Business Research Company published an Ultomiris Market Insights Report covering market size, trends and forecasts for 2026 to 2035. - The report says North America was the largest Ultomiris market in 2025. - The report identifies Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa as part of the global regional outlook. - Download a free sample of the report. - View the full report.
The details: - Ultomiris contains ravulizumab-cwvz, a monoclonal antibody that blocks the C5 protein in the immune complement system. - The drug prevents the immune system from attacking healthy cells. - Ultomiris is used in rare and severe autoimmune conditions, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. - Historical market growth has been driven by better diagnosis of rare autoimmune disorders. - Growth has also been supported by monoclonal antibody progress, broader reimbursement for biologic therapies, greater clinician understanding of complement system diseases and hospital-based infusion services. - Future growth is expected to be fueled by investment in rare disease drug development, more subcutaneous formulations, home infusion care, long-term disease management and therapies that lower treatment burden. - The report highlights the rising adoption of long-acting complement inhibitors, which can extend dosing intervals and improve compliance. - It also points to broader use of targeted autoimmune treatments, specialized rare-disease programs and patient-centered infusion models. - The report cites rising autoimmune disease prevalence as a key demand driver. - Arthritis Australia projected in February 2024 that by 2025 about 212,136 males and 362,137 females in Australia will have rheumatoid arthritis, with numbers rising further by 2040. - The report links rising healthcare spending to higher medication, administration, monitoring and research costs. - The UK’s Office for National Statistics said in May 2024 that U.S. healthcare spending rose 5.6% from 2022 to 2023, compared with 0.9% growth the prior year.
Between the lines: - The market story is less about one drug alone and more about how specialty care is shifting toward longer-acting treatments and more convenient delivery. - Stronger diagnosis and reimbursement can expand the addressable patient pool, which is critical in rare disease markets. - The focus on home infusion and subcutaneous options suggests health systems want to reduce clinic dependence and treatment burden.
What's next: - Continued investment in rare disease pipelines could widen the pipeline of complement-targeting therapies. - Adoption of subcutaneous and home-based care models may change where and how Ultomiris is administered. - The report’s forecasting tools and market scoring materials are positioned to help companies track opportunity by region and therapy trend. - The Business Research Company invites readers to contact its team for more information through the report page and company channels.
The bottom line: - Ultomiris sits in a market that is being pushed by better diagnosis, more spending and a shift toward longer-acting, lower-burden rare-disease treatments.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Business Times Australia
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.